3 Takeaways From Canopy Growth Corp’s (TSX:WEED) Q2 Earnings

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) just released earnings for the quarter ended just before legalization. Here’s what you need to know.

| More on:

Yesterday was a big day for the cannabis industry. Canopy Growth (TSX:WEED)(NYSE:CGC) released its first post-legalization earnings, and the results were … mixed. Although the report only factored in “limited test shipments into recreational channels,” it is our first early glimpse into how legalization is panning out for Canopy. It should be noted that these “test shipments” are valued just $700,000 and are therefore a tiny fraction of the company’s total recreational sales for the year. Nevertheless, this is a milestone earnings report that comes at a very pivotal time for Canopy.

So, how did Canada’s “king of cannabis” do in Q2?

We can start by looking at revenue growth.

Revenue growth slowed

Canopy’s revenue for Q2 was $23 million, which represents 33% growth over the same quarter last year, which is a pretty solid figure in itself; however, it is concerning that this is down from the 63% Canopy achieved in Q1. Drastic revenue growth reductions are usually not a good sign, especially in companies that have not yet become profitable. However, I should be clear once again that these Q3 results only reflected minuscule early recreational shipments. I fully expect Canopy’s revenue growth in Q3 to be extremely high.

Loss widens

Here’s the part of Canopy’s Q2 earnings that worries me the most: the company lost money yet again. Not only that, but the loss is way, way up: in Q2, Canopy lost $330 million compared to $1.6 million a year before. Of course, this loss factors in one-time costs like building infrastructure (e.g., new grow sites and physical storefronts) ahead of legalization. Nevertheless, a loss this big is a serious concern. But before getting too freaked out about it, we should look into the underlying causes.

Expenses up

The big reason Canopy’s loss widened in Q2 was that its expenses were up across the board. Sales and marketing costs grew from $7.6 million to $39 million. R&D costs roughly quadrupled. Share-based compensation expenses went into orbit, growing from $5.86 million to $45 million. A lot of these ballooning costs can be explained by the extensive preparations the company underwent ahead of legalization. Still, it has to be said: Canopy is burning through cash.

Bottom line

Canopy’s Q2 earnings report comes at a pivotal time for the company. After months of anticipation, we finally have a sneak peek into how it is doing post-legalization. Nevertheless, the total impact of legalization on the results reported yesterday was minuscule. Less than $1 million worth of recreational “test shipments” were included — compared to $23 million in total revenue. That is a drop in the bucket compared to what we’ll be seeing in Q3, which will factor in almost three full months of recreational sales.

On the surface, I think Canopy’s Q2 earnings are concerning. However, I also think that these earnings aren’t nearly as important as the ones we’ll see posted in three months. I would wait until then before taking a position in Canopy stock.

Fool contributor Andrew Button has no position in any of the stocks mentioned.

More on Investing

Blocks conceptualizing the Registered Retirement Savings Plan
Tech Stocks

Got $10,000? Should You Invest in an RRSP or TFSA

Thinking about an RRSP? Discover how investing can lead to significant tax savings and impact your retirement planning.

Read more »

doctor uses telehealth
Dividend Stocks

Power-Up Your TFSA: This TSX-Listed ETF Delivers Monthly Tax-Free Cash Flow

Looking for passive income in 2026? This TSX-listed ETF offers a massive 9.2% annual yield and monthly tax-free cash flow…

Read more »

A steel grain silo storage tank with solar panel in a yellow canola field in bloom in Alberta, Canada.
Dividend Stocks

Top Canadian Stocks to Buy With $7,000 in 2026

For investors looking to make the most of a $7,000 TFSA contribution, these Canadian stocks deserve a closer look.

Read more »

data analyze research
Bank Stocks

CIBC: Buy, Sell, or Hold in 2026?

CIBC (TSX:CM) stock had a wonderful 2025, but can another good year of gains be on the table as valuations…

Read more »

chart reflected in eyeglass lenses
Investing

Here’s the Average Canadian TFSA at Age 40

Find out how a TFSA can help Canadians aged 40 to 44 grow their savings while protecting gains from taxes.

Read more »

a man relaxes with his feet on a pile of books
Metals and Mining Stocks

What is the TFSA Contribution Limit for 2026

Maximize your investments: get all the details on the 2026 TFSA contribution limit and how to effectively use your TFSA.

Read more »

Canadian Dollars bills
Dividend Stocks

Top Canadian Stocks to Buy Right Now With $2,000

Your $2,000 today can become a productive asset that can grow over time if you buy the top Canadian stocks.

Read more »

dividends grow over time
Investing

3 Growth Stocks That Could Skyrocket in 2026 and Beyond

Given their solid underlying businesses, healthy growth prospects, and attractive valuations, these companies are excellent buys.

Read more »